Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?
In its first quarter 2025 investor letter, PGIM Jennison Health Sciences Fund highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focusing on developing and commercializing therapies for treating cystic fibrosis (CF). The one-month return of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 1.75%, and its shares lost 5.47% of their value over the last 52 weeks. On July 7, 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock closed at $459.41 per share, with a market capitalization of $117.975 billion.
PGIM Jennison Health Sciences Fund stated the following regarding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its first quarter 2025 investor letter:
"Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a commercial stage biopharmaceutical with a core franchise of small molecule cystic fibrosis transmembrane conductance regulator (CFTR) modulators for cystic fibrosis (CF), a genetic and progressively fatal respiratory disease. VRTX has built a unique and unrivaled market position as the dominant market leader in CF, having created and expanded the market into a nearly $10B franchise and growing with the approval of their next-gen CF triple therapy, Alyftrek, which we believe will drive top-line growth and margin expansion in 2025 onwards. VRTX is also developing an acute and chronic pain franchise. VRTX received approval in acute pain expect this launch to begin to contribute in 2H 2025. Pain as a potentially mega blockbuster category is increasingly becoming evident following a 6/7 hit rate for VX-548 in clinical trials (as well as previous-gen asset VX-150 going 2/2 itself). While market development will need to be done, which is true for any new class of drugs, and expectations for acute pain are appropriately measured despite positive feedback, creating a good setup for the early quarters of launch. Beyond CF and pain, VRTX has focused its pipeline around genetically driven diseases with the potential for a transformative clinical benefit. It currently spans 5 disease verticals: sickle cell/beta thalassemia, type 1 diabetes, apolipoprotein L1 (APOL-1) kidney disease, IgA nephropathy (from the recent acquisition of Alpine Immune Sciences), and alpha-1 antitrypsin disease. VRTX has had another strong start to the year and has delivered positively on several clinical trial readouts, as well as beat Q4 revenue estimates and maintained 2025 guidance."
A pharmacist delivering a specific medication to a patient in a specialty pharmacy.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 60 hedge fund portfolios held Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at the end of the first quarter, compared to 68 in the previous quarter. While we acknowledge the potential of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
In another article, we covered Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and shared the list of best fundamental stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
14 minutes ago
- CNBC
CNBC Daily Open: That's not how revisions to jobs numbers work
After U.S. jobs figures for May and June were revised significantly downward by the Bureau of Labor Statistics — slashing a combined 258,000 from previous figures — President Donald Trump, imputing political bias and data manipulation to BLS Commissioner Erika McEntarfer, revised her employment status to "terminated." Government officials from both sides of the political aisle had plenty to say about that. "Bottom line, Trump wants to cook the books," said Ron Wyden, the top Democrat on the Senate Finance Committee. Meanwhile, Republican Senator Rand Paul told NBC News that "you can't really make the numbers different or better by firing the people doing the counting." The move, indeed, does have a whiff of the Chinese government, in August 2023, stopping the release of youth unemployment rates because they were spiking to record highs. (Beijing resumed disseminating the data in January 2024.) A falling tree makes a sound, regardless of whether there's anyone around to hear it. Terminating the person who reports that noise won't suck sound waves back into a vacuum either. Markets, too, were vocal in their response to Trump's firing of McEntarfer as well as the dismal jobs report. On Friday, the three major U.S. indexes had their worst day in months, a sharp turn from the week prior, which saw consecutive days of record highs for the S&P 500 and Nasdaq Composite. This changes the calculus. With new tariffs due to take effect Aug. 7 — which could further slow hiring in the U.S. because of increased costs and uncertainties for companies — both the economy and markets might weaken further. Then it becomes a matter of whether the "TACO trade" — "Trump Always Chickens Out" — will, in the words of The Terminator, be appear in the U.S. jobs market. Nonfarm payrolls in July grew 73,000, lower than the Dow Jones estimate of a 100,000 gain. Unemployment edged up 10 basis points to 4.2%. June and May's jobs numbers were revised dramatically lower. Trump fires commissioner of labor statistics after jobs report. In a Truth Social post, the U.S. president accused BLS Commissioner Erika McEntarfer of being a political appointee who "faked the Jobs Numbers before the Election" and providing inaccurate data. BYD posts its first monthly delivery decline in 2025. China's largest EV maker shipped 341,030 units in July, a 9.7% drop from the previous month. Other domestic competitors, such as Li Auto and Nio, also recorded a month-on-month decline in July deliveries. U.S. stocks suffer their worst day in months. On Friday, the S&P 500 lost 1.6%, its worst day since May 21, breaking a 26-day streak when the index's moves remained within a 1% range. Asia-Pacific markets traded mixed Monday, while oil prices dipped on an output increase. [PRO] Robotaxis are becoming a reality. Waymo is, in the U.S., the market leader thus far, while Pony AI, WeRide and Baidu have been operating rides in China's larger cities. Analysts give their assessment on which company is likely to win the robotaxi race. Singapore's stock market is soaring. And the bull run is just getting started, experts say Once seen as a small, "unexciting" market for income-seeking investors, Singapore equities have taken a sharp turn upwards, surging to record highs. Major banks and market watchers signaling that the rally is just getting started. Building on its strong gains from last year, the benchmark Straits Times Index has advanced nearly 10% so far in 2025, outperforming the U.S. benchmark S&P 500 and several regional peers.
Business Insider
an hour ago
- Business Insider
Russia's inflation fight is working — at the cost of growth
Russia may be getting its spiraling inflation under control, but it comes at a growing economic cost, according to a think tank. "Current inflationary pressures, including underlying ones, are declining faster than previously forecast," Russia's central bank said last month. Russia's inflation fell from 8.2% in the first quarter to 4.8% in the second quarter, prompting its central bank to lower its key interest rate from 20% to 18%. "The economy continues to return to a balanced growth path," the central bank added. That phrase is just "a euphemism for anemic growth," wrote Alexander Kolyandr, a senior fellow at the Center for European Policy Analysis, on Thursday. The Bank of Russia expects Russia's economy to grow 1% to 2% this year. Meanwhile, the International Monetary Fund expects growth of 0.9%. Russia's central bank projects the key interest rate to average between 18.8% and 19.6% this year and fall to 12% to 13% next year — a shift from aggressive interest-rate hikes from mid-2023 to tame an overheating war-fueled economy. Such high rates were effective at cooling prices. But they have also made borrowing more expensive and dampened both consumer demand and business investment. Since its full-scale invasion of Ukraine triggered sweeping Western sanctions, Russia has kept its economy afloat through massive defense spending and revenue from oil and gas exports. But that momentum may be running out. Growth stalls as manufacturing contracts and momentum fades The country's GDP grew just 1.4% in the first quarter — a sharp slowdown from the previous quarter. In July, Russia's manufacturing sector posted its steepest contraction in three years, according to S&P Global's Purchasing Managers' Index. "Weak client demand and financial difficulties at customers" weighed on output and new orders, wrote S&P Global. Business confidence was the lowest in three years. The slowdown in manufacturing suggests Russia's wartime economy may be losing momentum, adding pressure on policymakers to strike a delicate balance. "For the Kremlin, a brief period of low growth is tolerable, though combined with lower oil prices, it would reduce fiscal revenues," CEPA's Kolyandr wrote. "The main gamble is that the cooling of the economy won't trigger a prolonged recession," he added. Russia's central bank now finds itself walking a tightrope: keeping inflation in check while avoiding a deeper downturn. Continued wartime spending could easily reignite inflation, but pulling back could deepen the slowdown, especially as foreign investment remains scarce and consumer confidence weak. Meanwhile, President Donald Trump is putting pressure on Russia to end its war with Ukraine with new penalties, including secondary tariffs. Last week, Trump announced a 25% tariff on India and a "penalty" for its purchases of Russian oil.
an hour ago
Asian markets are mixed after Wall St tumbles following poor US jobs report
BANGKOK -- Shares in Asia are mixed after Wall Street had its worst day since May following the release of weak U.S. jobs data. Markets in Asia had already reacted on Friday to U.S. President Donald Trump's announcement of sweeping tariffs on imports from many U.S. trading partners, posting moderate losses. The new import duties are set to take effect on Thursday. Tokyo's Nikkei 225 index lost 1.6%, bouncing back from bigger losses, to 40,134.97. The Hang Seng in Hong Kong edged 0.2% higher, to 24,589.21, while the Shanghai Composite index was nearly unchanged at 3,562.18. In South Korea, the Kospi surged 0.7% to 3,140.92. Australia's S&P/ASX 200 shed 0.2% to 8,643.00. Investors' worries about a weakening U.S. economy deepened after the latest report on job growth in the U.S. showed employers added just 73,000 jobs in July. That is sharply lower than economists expected. The Labor Department also reported that revisions shaved a stunning 258,000 jobs off May and June payrolls. 'The labor market, once a pillar of resilience, is now looking more like a late-cycle casualty, as soft data begin to replace soft landings in market discourse,' Stephen Innes of SPI Asset Management said in a commentary. U.S. futures edged 0.3% higher, however, early Monday. On Friday, the S&P 500 fell 1.6%, its biggest decline since May 21 and its fourth straight loss. It closed at 6,238.01, posting a 2.4% loss for the week. The Dow Jones Industrial Average fell 1.2% to 43,588.58, while the Nasdaq composite fell 2.2% to finish at 20,650.13. Internet retail giant Amazon fell 8.3%, despite reporting encouraging profit and sales for its most recent quarter. Technology behemoth Apple fell 2.5% after also beating Wall Street's profit and revenue forecasts. Both companies face tougher operating conditions because of tariffs, with Apple forecasting a $1.1 billion hit from the fees in the current quarter. Trump's decision to order the immediate firing of the head of the government agency that produces the monthly jobs figures raised concern over whether there might be interference in future data. The surprisingly weak hiring numbers led investors to step up their expectations the Federal Reserve may cut interest rates in September. The yield on the 10-year Treasury fell to 4.21% from 4.39% just before the hiring report was released. That's a big move for the bond market. The yield on the two-year Treasury, which more closely tracks expectations for Fed actions, plunged to 3.68% from 3.94% just prior to the report's release. The Fed has held rates steady since December. A cut in rates would give the job market and overall economy a boost, but it could also risk fueling inflation, which is hovering stubbornly above the central bank's 2% target. An update on Thursday for the Fed's preferred measure of inflation showed that prices ticked higher in June, rising to 2.6% from 2.4% in May. The Fed held rates steady again at its most recent meeting this week. Fed Chair Jerome Powell has been pressured by Trump to cut the benchmark rate, though that decision isn't his to make alone, but belongs to the 12 members of the Federal Open Market Committee. Businesses, investors and the Fed have been operating under a cloud of uncertainty from Trump's tariff policy. Companies have been warning investors that unpredictable policies, with some tariffs already in effect while others change or get extended, make it difficult to plan ahead. Walmart, Procter & Gamble and many others also have warned about import taxes raising costs, eating into profits and raising prices for consumers. In other dealings early Monday, U.S, benchmark crude oil lost 18 cents to $67.15 per barrel. Brent crude, the international standard, fell 23 cents to $69.44 per barrel. The U.S. dollar rose to 147.80 Japanese yen from 147.26 yen. The euro weakened to $1.1577 from $1.1598.
